Nine Masts Capital’s Humacyte HUMA Stock Holding History

Nine Masts Capital’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-54,535	Closed	-$33.1K	–	231
2026 Q1	$33.1K	Buy	+54,535	New	+$56.7K	﹤0.01%	208

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Nine Masts Capital's HUMA Position: Q2 2026 in Review

Nine Masts Capital sold out of Humacyte (HUMA) in Q2 2026, closing a stake of 54,535 shares — an estimated $33.1K sold.

Nine Masts Capital first reported a position in HUMA in Q1 2026 and held it in 1 quarter. The position peaked at $33.1K in Q1 2026. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Nine Masts Capital reported no remaining Humacyte position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 54,535 Humacyte shares in Q2 2026, an estimated $33.1K.
Nine Masts Capital first reported a position in Humacyte in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Humacyte position peaked at $33.1K in Q1 2026.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.